


- 136 -





5 What is claimed:

1. A compound of the formulae:




wherein:

- 10  $R_1$  and  $R_1$  are independently selected from H, halogen,  $-CF_3$ ,  $-OH$ ,  $-C_1-C_{10}$  alkyl,  $-S-C_1-C_{10}$  alkyl,  $-C_1-C_{10}$  alkoxy,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-HN(C_1-C_6)$ ,  $-N(C_1-C_6)_2$ , phenyl,  $-O$ -phenyl,  $-S$ -phenyl, benzyl,  $-O$ -benzyl,  $-S$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy,  $-NO_2$ ,  $-NH_2$ ,  $-CN$ ,  $-CF_3$ , or  $-OH$ ;
- 15 or a moiety of the formulae:



0967021-092900

- 137 -



$\text{R}_6$  is selected from H,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{C}(\text{O})\text{CH}_3$ , phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{NO}_2$ ,  $-\text{NH}_2$ ,  $-\text{CN}$ ,  $-\text{CF}_3$ , or  $-\text{OH}$ ;

$\text{R}_7$  is selected from  $-(\text{CH}_2)_n\text{-COOH}$ ,  $-(\text{CH}_2)_n\text{-N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$ ,  $-(\text{CH}_2)_n\text{-NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$ ,  $-\text{CF}_3$ ,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_3\text{-C}_5$  cycloalkyl,  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$ ,  $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$ , pyridinyl, thienyl, furyl, pyrrolyl, quinolyl,  $(\text{CH}_2)_n$ phenyl, phenyl, -O-phenyl, benzyl, -O-benzyl, adamantyl, or morpholinyl,  $-(\text{CH}_2)_n$ -phenyl-O-phenyl,  $-(\text{CH}_2)_n$ -phenyl- $\text{CH}_2$ -phenyl,  $-(\text{CH}_2)_n$ -O-phenyl- $\text{CH}_2$ -phenyl,  $-(\text{CH}_2)_n$ -phenyl-(O- $\text{CH}_2$ -phenyl) $_2$ , the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{NH}_2$ ,  $-\text{NO}_2$ ,  $-\text{CF}_3$ ,  $\text{CO}_2\text{H}$ , or  $-\text{OH}$ ;

$\text{R}_2$  is selected from H, halogen,  $-\text{CF}_3$ ,  $-\text{OH}$ ,  $-\text{C}_1\text{-C}_{10}$  alkyl, preferably  $-\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_{10}$  alkoxy, preferably  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{CHO}$ ,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $-\text{NH}_2$ ,  $-\text{NH}\text{-C}_1\text{-C}_6$  alkyl,  $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$ ,  $-\text{N}\text{-SO}_2\text{-C}_1\text{-C}_6$  alkyl, or  $-\text{SO}_2\text{-C}_1\text{-C}_6$  alkyl;

$\text{R}_3$  is selected from H,  $-\text{CF}_3$ ,  $\text{C}_1\text{-C}_6$  lower alkyl,  $\text{C}_1\text{-C}_6$  lower alkoxy,  $\text{C}_3\text{-C}_{10}$  cycloalkyl,  $-\text{C}_1\text{-C}_6$  alkyl,  $-\text{C}_3\text{-C}_{10}$  cycloalkyl,  $-\text{CHO}$ , halogen,  $(\text{CH}_2)_n\text{C}(\text{O})\text{NH}_2$  or a moiety of the formula  $-\text{L}^1\text{-M}^1$ :

- 138 -

5 L<sup>1</sup> indicates a linking or bridging group of the formulae  $-(CH_2)_n-$ ,  $-S-$ ,  $-O-$ ,  
 $-C(O)-$ ,  $-(CH_2)_n-C(O)-$ ,  $-(CH_2)_n-C(O)-(CH_2)_n-$ ,  $-(CH_2)_n-O-(CH_2)_n-$ , or  $-(CH_2)_n-S-(CH_2)_n-$ ,  
C(O)C(O)X,  $-(CH_2)_n-N-(CH_2)_n-$ ;

10 M<sup>1</sup> is selected from:

a) H, the group of C<sub>1</sub>-C<sub>6</sub> lower alkyl, C<sub>1</sub>-C<sub>6</sub> lower alkoxy, C<sub>3</sub>-C<sub>10</sub> cycloalkyl,  
phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted  
by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl,  
C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, or -CF<sub>3</sub>; or

15 b) a five-membered heterocyclic ring containing one or two ring  
heteroatoms selected from N, S or O including, but not limited to, furan, pyrrole,  
thiophene, imidazole, pyrazole, isothiazole, isoxazole, pyrrolidine, pyrroline,  
imidazolidine, pyrazolidine, pyrazole, pyrazoline, imidazole, tetrazole, oxathiazole,  
20 the five-membered heterocyclic ring being optionally substituted by from 1 to 3  
substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy,  
preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, or -CF<sub>3</sub>; or

25 c) a six-membered heterocyclic ring containing one, two or three ring  
heteroatoms selected from N, S or O including, but not limited to, pyran, pyridine,  
pyrazine, pyrimidine, pyridazine, piperidine, piperazine, tetrazine, thiazine,  
thiadiazine, oxazine, or morpholine, the six-membered heterocyclic ring being  
optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl,  
preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -CHO, -NO<sub>2</sub>, -NH<sub>2</sub>, -  
30 CN, -CF<sub>3</sub> or -OH; or

006260-1204960


Sub  
A1

- 139 -

- 5 d) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including, but not limited to benzofuran, chromene, indole, isoindole, indoline, isoindoline, naphthalene, purine, indolizine, indazole, quinoline, isoquinoline, quinolizine, quinazoline, cinnoline, phthalazine, or naphthyridine, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -CHO, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, -CF<sub>3</sub> or -OH;

- 15 R<sub>4</sub> is selected from the group of C<sub>1</sub>-C<sub>6</sub> lower alkyl, C<sub>1</sub>-C<sub>6</sub> lower alkoxy, -(CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>-S-(CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>5</sub> cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>5</sub> cycloalkyl, or the groups of:

- a) -(CH<sub>2</sub>)<sub>n</sub>-phenyl-O-phenyl, -(CH<sub>2</sub>)<sub>n</sub>-phenyl-CH<sub>2</sub>-phenyl, -(CH<sub>2</sub>)<sub>n</sub>-O-phenyl-CH<sub>2</sub>-phenyl, -(CH<sub>2</sub>)<sub>n</sub>-phenyl-(O-CH<sub>2</sub>-phenyl)<sub>2</sub>, or a moiety of the formulae:



- 25 wherein n is independently selected in each appearance as an integer from 0 to 3, preferably 0 to 2, more preferably 0 to 1, Y is C<sub>3</sub>-C<sub>5</sub> cycloalkyl, phenyl, benzyl, naphthyl, pyridinyl, quinolyl, furyl, thienyl or pyrrolyl; rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF<sub>3</sub>, -


006260-12044960

Sub  
H1

- 140 -

- 5 OH,  $-C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy,  $-NH_2$ ,  $-NO_2$  or a five membered heterocyclic ring containing one heteroatom selected from N, S, or O, preferably S or O; or

b) a moiety of the formulae  $-(CH_2)_n-A$ ,  $-(CH_2)_n-S-A$ , or  $-(CH_2)_n-O-A$ , wherein A is the moiety:




wherein

D is H,  $C_1-C_6$  lower alkyl,  $C_1-C_6$  lower alkoxy, or  $-CF_3$ ;


B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen,  $-CF_3$ ,  $-OH$ ,  $-C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy, or  $-NO_2$ ; or

15

c) a moiety of the formulae:



- 141 -



wherein Z is O or S and the phenyl and pyrimidinyl rings of each moiety are optionally and independently substituted by from 1 to 3 substituents selected from halogen,  $-\text{CF}_3$ ,  $-\text{OH}$ ,  $-\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{NH}_2$ , or  $-\text{NO}_2$ ; or

d) a moiety of the formula  $-\text{L}^2\text{-M}^2$ , wherein:

$\text{L}^2$  indicates a linking or bridging group of the formulae  $-(\text{CH}_2)_n$ ,  $-\text{S}-$ ,  $-\text{O}-$ ,  $-\text{SO}_2-$ ,  $-\text{C}(\text{O})-$ ,  $-(\text{CH}_2)_n-\text{C}(\text{O})-$ ,  $-(\text{CH}_2)_n-\text{C}(\text{O})-(\text{CH}_2)_n-$ ,  $-(\text{CH}_2)_n-\text{O}-(\text{CH}_2)_n-$ , or  $-(\text{CH}_2)_n-\text{S}-(\text{CH}_2)_n-$ ,  $-\text{C}(\text{O})\text{C}(\text{O})\text{X}$ ;

where X = O, N

$\text{M}^2$  is selected from the group of  $\text{C}_1\text{-C}_6$  lower alkyl,  $\text{C}_1\text{-C}_6$  lower alkoxy,  $\text{C}_3\text{-C}_{10}$  cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being

Sub  
 AI

006260-1204960

- 142 -

5 optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, or -CF<sub>3</sub>; or

Sub A1  
10 i) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, pyrrolidine, or tetrazole, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, or -CF<sub>3</sub>; or

15 ii) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O including, but not limited to pyridine, pyrimidine, piperidine, piperazine, or morpholine, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -CHO, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, -CF<sub>3</sub> or -OH; or

20




25 iii) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including, but not limited to benzofuran, indole, indoline, naphthalene, purine, or quinoline, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -CHO, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, -CF<sub>3</sub> or -OH;

30 n is an integer from 0 to 3;

006260" T2044960

- 143 -

- 5  $R_5$  is selected from  $-\text{COOH}$ ,  $-\text{C}(\text{O})-\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{COOH}$ ,  $(\text{CH}_2)_n-\text{CH}=\text{CH}-\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{tetrazole}$ ,  $-\text{CH}_2\text{-phenyl-C}(\text{O})\text{-benzothiazole}$ ,  
or



or a moiety selected from the formulae  $-\text{L}^3-\text{M}^3$ ;



- wherein  $\text{L}^3$  is a bridging or linking moiety selected from a chemical bond,  $-(\text{CH}_2)_n-$ , -  
15  $\text{S}-$ ,  $-\text{O}-$ ,  $-\text{SO}_2-$ ,  $-\text{C}(\text{O})-$ ,  $-(\text{CH}_2)_n-\text{C}(\text{O})-$ ,  $-(\text{CH}_2)_n-\text{C}(\text{O})-(\text{CH}_2)_n-$ ,  $-(\text{CH}_2)_n-\text{O}-(\text{CH}_2)_n-$ ,  
 $(\text{CH}_2)_n-\text{S}-(\text{CH}_2)_n-$ ,  $-\text{C}(\text{Z})-\text{N}(\text{R}_6)-$ ,  $-\text{C}(\text{Z})-\text{N}(\text{R}_6)-(\text{CH}_2)_n-$ ,  $-\text{C}(\text{O})-\text{C}(\text{Z})-\text{N}(\text{R}_6)-$ ,  $-\text{C}(\text{O})-$   
 $\text{C}(\text{Z})-\text{N}(\text{R}_6)-(\text{CH}_2)_n-$ ,  $-\text{C}(\text{Z})-\text{NH}-\text{SO}_2-$ ,  $-\text{C}(\text{Z})-\text{NH}-\text{SO}_2-(\text{CH}_2)_n-$ ,  $-(\text{CH}_2)_n-\text{S}-(\text{CH}_2)_n-$ , -  
 $(\text{CH}_2)_n-\text{SO}-(\text{CH}_2)_n-$ ,  $-(\text{CH}_2)_n-\text{SO}_2-(\text{CH}_2)_n-$ , or  $-(\text{CH}_2)_n-\text{CH}=\text{CH}-(\text{CH}_2)_n-\text{O}-$ ;

- $\text{M}^3$  is selected from the group of  $-\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{C}(\text{O})-$   
20  $\text{COOH}$ , tetrazole,




- 144 -

5



10

or




where  $R_8$ ,  $R_9$  or  $R_{10}$  can be attached anywhere in the cyclic or bicyclic system,  
n is an integer from 0 to 3;

15  $R_8$ , in each appearance, is independently selected from H,  $-\text{COOH}$ ,  $-(\text{CH}_2)_n-$   
 $\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$ , tetrazole,  $-\text{C}(\text{O})-\text{NH}_2$ ,  $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{NH}_2$ ,

00677021-092900

- 145 -






n is an integer from 0 to 3;

10  $R_9$  is selected from H, halogen,  $-CF_3$ ,  $-OH$ ,  $-COOH$ ,  $-(CH_2)_n-COOH$ ,  $-(CH_2)_n-C(O)-COOH$ ,  $-C_1-C_6$  alkyl,  $-O-C_1-C_6$  alkyl,  $-NH(C_1-C_6$  alkyl), or  $-N(C_1-C_6$  alkyl)<sub>2</sub>;

n is an integer from 0 to 3;


$R_{10}$  is selected from the group of H, halogen,  $-CF_3$ ,  $-OH$ ,  $-(CH_2)_n-COOH$ ,  $-(CH_2)_n-C(O)-COOH$ ,  $-C_1-C_6$  alkyl,  $-O-C_1-C_6$  alkyl,  $-NH(C_1-C_6$  alkyl),  $-N(C_1-C_6$  alkyl)<sub>2</sub>,



006260" T2022960

Sub  
 AI


- 146 -




$R_{11}$  is selected from H,  $\text{C}_1\text{-C}_6$  lower alkyl,  $\text{C}_1\text{-C}_6$  cycloalkyl,  $-\text{CF}_3$ ,  $-\text{COOH}$ ,  $-(\text{CH}_2)_n\text{-COOH}$ ,  $-(\text{CH}_2)_n\text{-C(O)-COOH}$ ,

006260 T207960 Sub A1

- 147 -




with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of  $R_5$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ , and/or  $R_{11}$  shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae:  $-C(O)-NH_2$ ,  $-(CH_2)_n-C(O)-NH_2$ ,



$n$  is an integer from 0 to 3;

or a pharmaceutically acceptable salt thereof.

2. A compound of Claim 1 of the formula:



wherein:

006260-12072960

- 148 -

5             $R_1$  and  $R_1$  are independently selected from H, halogen,  $-CF_3$ ,  $-OH$ ,  $-C_1-C_{10}$  alkyl,  $-S-C_1-C_{10}$  alkyl,  $C_1-C_{10}$  alkoxy,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-HN(C_1-C_6)$ ,  $-N(C_1-C_6)_2$ , phenyl,  $-O$ -phenyl,  $-S$ -phenyl, benzyl,  $-O$ -benzyl, or  $-S$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy,  $-NO_2$ ,  $-NH_2$ ,  $-CN$ ,  $-CF_3$ , or  $-OH$ ;

10             $R_2$  is selected from H, halogen,  $-CF_3$ ,  $-OH$ ,  $-C_1-C_{10}$  alkyl, preferably  $-C_1-C_6$  alkyl,  $C_1-C_{10}$  alkoxy, preferably  $C_1-C_6$  alkoxy,  $-CHO$ ,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-NH-C_1-C_6$  alkyl,  $-N(C_1-C_6 \text{ alkyl})_2$ ,  $-N-SO_2-C_1-C_6$  alkyl, or  $-SO_2-C_1-C_6$  alkyl;

15             $R_3$  is selected from H,  $-CF_3$ ,  $C_1-C_6$  lower alkyl,  $C_1-C_6$  lower alkoxy,  $C_3-C_{10}$  cycloalkyl,  $-C_1-C_6$  alkyl,  $-C_3-C_{10}$  cycloalkyl,  $-CHO$ , halogen, or  $(CH_2)_n C(O)NH_2$  or a moiety of the formula  $-L^1-M^1$ :

20             $L^1$  indicates a linking or bridging group of the formulae  $-(CH_2)_n-$ ,  $-S-$ ,  $-O-$ ,  $-C(O)-$ ,  $-(CH_2)_n-C(O)-$ ,  $-(CH_2)_n-C(O)-(CH_2)_n-$ ,  $-(CH_2)_n-O-(CH_2)_n-$ , or  $-(CH_2)_n-S-(CH_2)_n-$ ,  $C(O)C(O)X$ ,  $-(CH_2)_n-N-(CH_2)_n-$ ,


25             $M^1$  is selected from: H,  $C_1-C_6$  lower alkyl,  $C_1-C_6$  lower alkoxy,  $C_3-C_{10}$  cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen,  $C_1-C_{10}$  alkyl, preferably  $C_1-C_6$  alkyl,  $C_1-C_{10}$  alkoxy, preferably  $C_1-C_6$  alkoxy,  $-NO_2$ ,  $-NH_2$ ,  $-CN$ , or  $-CF_3$ ;

$R_4$  is a moiety of the formulae  $-(CH_2)_n-A$ ,  $-(CH_2)_n-S-A$ , or  $-(CH_2)_n-O-A$ , wherein A is the moiety:

Sub  
AF  
cont

09577021-092900

- 149 -




wherein

D is H, C<sub>1</sub>-C<sub>6</sub> lower alkyl, C<sub>1</sub>-C<sub>6</sub> lower alkoxy, or -CF<sub>3</sub>;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF<sub>3</sub>, -OH, -C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, or -NO<sub>2</sub>; or a pharmaceutically acceptable salt thereof.


3. A compound of Claim 2 wherein R<sub>4</sub> is the moiety:



B and C are phenyl optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF<sub>3</sub>, -OH, -C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, or -NO<sub>2</sub>; and R<sub>1</sub>, R<sub>1</sub><sup>1</sup>, R<sub>2</sub>, R<sub>3</sub>, R<sub>5</sub>, L<sup>1</sup>, M<sup>1</sup> and D are as defined in Claim 2; or a pharmaceutically acceptable salt thereof.

4. A compound of Claim 1 having the formulae:


- 150 -



wherein:

R<sub>1</sub> and R<sub>1'</sub> are independently selected from H, halogen, -CF<sub>3</sub>, -OH, -C<sub>1</sub>-C<sub>10</sub> alkyl, preferably -C<sub>1</sub>-C<sub>6</sub> alkyl, -S-C<sub>1</sub>-C<sub>10</sub> alkyl, preferably -S-C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -HN(C<sub>1</sub>-C<sub>6</sub>), -N(C<sub>1</sub>-C<sub>6</sub>)<sub>2</sub>, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, -CF<sub>3</sub>, or -OH;


or R<sub>1</sub> and R<sub>1'</sub> are independently a moiety of the formulae:



Sub  
A  
cont

006260" T2074960

- 151 -



$\text{R}_6$  is selected from H,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{C}(\text{O})\text{CH}_3$ , phenyl,  $-\text{O}$ -phenyl, benzyl,  $-\text{O}$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{NO}_2$ ,  $-\text{NH}_2$ ,  $-\text{CN}$ ,  $-\text{CF}_3$ , or  $-\text{OH}$ ;

15  $\text{R}_7$  is selected from  $-(\text{CH}_2)_n\text{-COOH}$ ,  $-(\text{CH}_2)_n\text{-N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$ ,  $-(\text{CH}_2)_n\text{-NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$ ,  $-\text{CF}_3$ ,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_3\text{-C}_5$  cycloalkyl,  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$ ,  $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$ , pyridinyl, thienyl, furyl, pyrrolyl, quinolyl,  $(\text{CH}_2)_n$ phenyl, phenyl,  $-\text{O}$ -phenyl, benzyl,  $-\text{O}$ -benzyl, adamantyl, or morpholinyl,  $-(\text{CH}_2)_n$ -phenyl- $-\text{O}$ -phenyl,  $-(\text{CH}_2)_n$ -phenyl- $\text{CH}_2$ -phenyl,  $-(\text{CH}_2)_n$ - $-\text{O}$ -phenyl- $\text{CH}_2$ -phenyl,  $-(\text{CH}_2)_n$ -phenyl- $(-\text{O}-\text{CH}_2\text{-phenyl})_2$ , the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{NH}_2$ ,  $-\text{NO}_2$ ,  $-\text{CF}_3$ ,  $\text{CO}_2\text{H}$ , or  $-\text{OH}$ ;

20  $\text{R}_2$  is selected from H, halogen,  $-\text{CF}_3$ ,  $-\text{OH}$ ,  $-\text{C}_1\text{-C}_{10}$  alkyl, preferably  $-\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_{10}$  alkoxy, preferably  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{CHO}$ ,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $-\text{NH}_2$ ,  $-\text{NH}-\text{C}_1\text{-C}_6$  alkyl,  $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$ ,  $-\text{N}-\text{SO}_2\text{-C}_1\text{-C}_6$  alkyl, or  $-\text{SO}_2\text{-C}_1\text{-C}_6$  alkyl;

25  $\text{R}_3$  is selected from H,  $-\text{CF}_3$ ,  $\text{C}_1\text{-C}_6$  lower alkyl,  $\text{C}_1\text{-C}_6$  lower alkoxy,  $\text{C}_3\text{-C}_{10}$  cycloalkyl,  $-\text{C}_1\text{-C}_6$  alkyl,  $-\text{C}_3\text{-C}_{10}$  cycloalkyl,  $-\text{CHO}$ , halogen,  $(\text{CH}_2)_n\text{C}(\text{O})\text{NH}_2$  or a moiety of the formula  $-\text{L}^1\text{-M}^1$ :

Sub  
 A1  
 Cont 0

006260.1207960



- 152 -

5 L<sup>1</sup> indicates a linking or bridging group of the formulae  $-(CH_2)_n-$ ,  $-S-$ ,  $-O-$ ,  $-C(O)-$ ,  $-(CH_2)_n-C(O)-$ ,  $-(CH_2)_n-C(O)-(CH_2)_n-$ ,  $-(CH_2)_n-O-(CH_2)_n-$ , or  $-(CH_2)_n-S-(CH_2)_n-$ ,  $C(O)C(O)X$ ,  $-(CH_2)_n-N-(CH_2)_n$

M<sup>1</sup> is selected from:

10 a) H, the group of C<sub>1</sub>-C<sub>6</sub> lower alkyl, C<sub>1</sub>-C<sub>6</sub> lower alkoxy, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, or -CF<sub>3</sub>; or

15 b) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, isothiazole, isoxazole, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazole, pyrazoline, imidazole, tetrazole, oxathiazole, 20 the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, or -CF<sub>3</sub>; or

25 c) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O including, but not limited to, pyran, pyridine, pyrazine, pyrimidine, pyridazine, piperidine, piperazine, tetrazine, thiazine, thiadiazine, oxazine, or morpholine, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -CHO, -NO<sub>2</sub>, -NH<sub>2</sub>, - 30 CN, -CF<sub>3</sub> or -OH; or


00667021.092900  
Sub  
A1  
cont

- 153 -

- 5 d) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including, but not limited to benzofuran, chromene, indole, isoindole, indoline, isoindoline, naphthalene, purine, indolizine, indazole, quinoline, isoquinoline, quinolizine, quinazoline, cinnoline, phthalazine, or naphthyridine, the bicyclic ring moiety being  
10 optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -CHO, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, -CF<sub>3</sub> or -OH;

- 15 R<sub>4</sub> is selected from the group of C<sub>1</sub>-C<sub>6</sub> lower alkyl, C<sub>1</sub>-C<sub>6</sub> lower alkoxy, - (CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>-S-(CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>5</sub> cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>5</sub> cycloalkyl, or the groups of:

- a) a moiety of the formulae -(CH<sub>2</sub>)<sub>n</sub>-A, -(CH<sub>2</sub>)<sub>n</sub>-S-A, or -(CH<sub>2</sub>)<sub>n</sub>-O-A, wherein A is the moiety:



- 20 wherein

D is H, C<sub>1</sub>-C<sub>6</sub> lower alkyl, C<sub>1</sub>-C<sub>6</sub> lower alkoxy, or -CF<sub>3</sub>;

- B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably  
25 1 to 2, substituents selected from H, halogen, -CF<sub>3</sub>, -OH, -C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, or -NO<sub>2</sub>; or

- b) a moiety of the formula -L<sup>2</sup>-M<sup>2</sup>, wherein:

- 154 -

5           L<sup>2</sup> indicates a linking or bridging group of the formulae  $-(CH_2)_n-$ ,  $-S-$ ,  $-O-$ ,  $-SO_2-$ ,  $-C(O)-$ ,  $-(CH_2)_n-C(O)-$ ,  $-(CH_2)_n-C(O)-(CH_2)_n-$ ,  $-(CH_2)_n-O-(CH_2)_n-$ , or  $-(CH_2)_n-S-(CH_2)_n-$ ,  $-C(O)C(O)X$ ;  
where X = O, N

10           M<sup>2</sup> is selected from the group of C<sub>1</sub>-C<sub>6</sub> lower alkyl, C<sub>1</sub>-C<sub>6</sub> lower alkoxy, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy,  $-NO_2$ ,  $-NH_2$ ,  $-CN$ , or  $-CF_3$ ; or

15           i)     a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, pyrrolidine, or tetrazole, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected  
20     from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy,  $-NO_2$ ,  $-NH_2$ ,  $-CN$ , or  $-CF_3$ ; or

          ii)     a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O including, but not limited to pyridine, pyrimidine, piperidine, piperazine, or morpholine, the six-membered heterocyclic ring  
25     being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy,  $-CHO$ ,  $-NO_2$ ,  $-NH_2$ ,  $-CN$ ,  $-CF_3$  or  $-OH$ ; or

30           iii)    a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including,


006260-1221-092900  
Sub  
Alf  
cm

- 155 -

5 but not limited to benzofuran, indole, indoline, naphthalene, purine, or quinoline, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen,  $C_1$ - $C_{10}$  alkyl, preferably  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_{10}$  alkoxy, preferably  $C_1$ - $C_6$  alkoxy, -CHO, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, -CF<sub>3</sub> or -OH;

10 n is an integer from 0 to 3;

R<sub>9</sub> is selected from -COOH, -C(O)-COOH, -(CH<sub>2</sub>)<sub>n</sub>-C(O)-COOH, -(CH<sub>2</sub>)<sub>n</sub>-COOH, (CH<sub>2</sub>)<sub>n</sub>-CH=CH-COOH, -(CH<sub>2</sub>)<sub>n</sub>-tetrazole, -CH<sub>2</sub>-phenyl-C(O)-benzothiazole, or



15


or a moiety selected from the formulae  $-L^3-M^3$ ;

20 wherein L<sup>3</sup> is a bridging or linking moiety selected from a chemical bond, -(CH<sub>2</sub>)<sub>n</sub>-, -S-, -O-, -SO<sub>2</sub>-, -C(O)-, -(CH<sub>2</sub>)<sub>n</sub>-C(O)-, -(CH<sub>2</sub>)<sub>n</sub>-C(O)-(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>n</sub>-S-(CH<sub>2</sub>)<sub>n</sub>-, -C(Z)-N(R<sub>6</sub>)-, -C(Z)-N(R<sub>6</sub>)-(CH<sub>2</sub>)<sub>n</sub>-, -C(O)-C(Z)-N(R<sub>6</sub>)-, -C(O)-C(Z)-N(R<sub>6</sub>)-(CH<sub>2</sub>)<sub>n</sub>-, -C(Z)-NH-SO<sub>2</sub>-, -C(Z)-NH-SO<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>n</sub>-S-(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>n</sub>-SO-(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>n</sub>-SO<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-, or -(CH<sub>2</sub>)<sub>n</sub>-CH=CH-(CH<sub>2</sub>)<sub>n</sub>-O-;

006260-T204960  
 Sub  
 Af  
 cm

- 156 -

5  $M^3$  is selected from the group of  $-\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{C(O)}-\text{COOH}$ , tetrazole,



where  $R_8$ ,  $R_9$  or  $R_{10}$  can be attached anywhere in the cyclic or bicyclic system,  
 $n$  is an integer from 0 to 3;

15


$R_8$ , in each appearance, is independently selected from H,  $-\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{C(O)}-\text{COOH}$ , tetrazole,  $-\text{C(O)}-\text{NH}_2$ ,  $-(\text{CH}_2)_n-\text{C(O)}-\text{NH}_2$ ,

006260-1204960

Sub  
 P1  
 Cont

- 157 -

5






n is an integer from 0 to 3;

R<sub>9</sub> is selected from H, halogen, -CF<sub>3</sub>, -OH, -COOH, -(CH<sub>2</sub>)<sub>n</sub>-COOH, -(CH<sub>2</sub>)<sub>n</sub>-C(O)-COOH, -C<sub>1</sub>-C<sub>6</sub> alkyl, -O-C<sub>1</sub>-C<sub>6</sub> alkyl, -NH(C<sub>1</sub>-C<sub>6</sub> alkyl), or -N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>;

n is an integer from 0 to 3;

R<sub>10</sub> is selected from the group of H, halogen, -CF<sub>3</sub>, -OH, -(CH<sub>2</sub>)<sub>n</sub>-COOH, -(CH<sub>2</sub>)<sub>n</sub>-C(O)-COOH, -C<sub>1</sub>-C<sub>6</sub> alkyl, -O-C<sub>1</sub>-C<sub>6</sub> alkyl, -NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>,



006260-1202960


Sub  
 A1  
 m

10


15

- 158 -


5








or




or



10



, or




15

n is an integer from 0 to 3;


006260" T2042960 A1 cmf

- 159 -

- 5  $R_{11}$  is selected from H,  $C_1$ - $C_6$  lower alkyl,  $C_1$ - $C_6$  cycloalkyl,  $-CF_3$ ,  $-COOH$ ,  $-(CH_2)_n-COOH$ ,  $-(CH_2)_n-C(O)-COOH$ ,




with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of  $R_5$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ , and/or  $R_{11}$  shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae:  $-C(O)-NH_2$ ,  $-(CH_2)_n-C(O)-NH_2$ ,




$n$  is an integer from 0 to 3;

- 15 or a pharmaceutically acceptable salt thereof.

5. A compound of Claim 1 having the formulae:



or




wherein:

006260-1202960



- 160 -

- 5  $R_1$  is selected from H, halogen,  $-CF_3$ ,  $-OH$ ,  $-C_1-C_{10}$  alkyl, preferably  $-C_1-C_6$  alkyl,  $-S-C_1-C_{10}$  alkyl, preferably  $-S-C_1-C_6$  alkyl,  $C_1-C_{10}$  alkoxy, preferably  $C_1-C_6$  alkoxy,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-HN(C_1-C_6)$ ,  $-N(C_1-C_6)_2$ , phenyl,  $-O$ -phenyl,  $-S$ -phenyl, benzyl,  $-O$ -benzyl,  $-S$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy,  $-NO_2$ ,  $-NH_2$ ,  $-CN$ ,  $-CF_3$ , or  $-OH$ ;  
10 or  $R_1$  and  $R_2$  are independently a moiety of the formulae:



- 20  $R_6$  is selected from H,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy,  $-C(O)CH_3$ , phenyl,  $-O$ -phenyl, benzyl,  $-O$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy,  $-NO_2$ ,  $-NH_2$ ,  $-CN$ ,  $-CF_3$ , or  $-OH$ ;

006260-1204960

Al  
cont

- 161 -

5  $R_1$  is selected from  $-(CH_2)_n-COOH$ ,  $-(CH_2)_n-N-(C_1-C_6 \text{ alkyl})_2$ ,  $-(CH_2)_n-NH-(C_1-C_6 \text{ alkyl})$ ,  $-CF_3$ ,  $C_1-C_6 \text{ alkyl}$ ,  $C_3-C_5 \text{ cycloalkyl}$ ,  $C_1-C_6 \text{ alkoxy}$ ,  $-NH-(C_1-C_6 \text{ alkyl})$ ,  $-N-(C_1-C_6 \text{ alkyl})_2$ , pyridinyl, thienyl, furyl, pyrrolyl, quinolyl,  $(CH_2)_n$ phenyl, phenyl-O-phenyl, benzyl, -O-benzyl, adamantyl, or morpholinyl,  $-(CH_2)_n$ -phenyl-O-phenyl,  $-(CH_2)_n$ -phenyl- $CH_2$ -phenyl,  $-(CH_2)_n$ -O-phenyl- $CH_2$ -phenyl,  $-(CH_2)_n$ -phenyl-(O- $CH_2$ -phenyl)<sub>2</sub>, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen,  $C_1-C_6 \text{ alkyl}$ ,  $C_1-C_6 \text{ alkoxy}$ ,  $-NH_2$ ,  $-NO_2$ ,  $-CF_3$ ,  $CO_2H$ , or  $-OH$ ;

15  $R_2$  is selected from H, halogen,  $-CF_3$ ,  $-OH$ ,  $-C_1-C_{10} \text{ alkyl}$ , preferably  $-C_1-C_6 \text{ alkyl}$ ,  $C_1-C_{10} \text{ alkoxy}$ , preferably  $C_1-C_6 \text{ alkoxy}$ ,  $-CHO$ ,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-NH-C_1-C_6 \text{ alkyl}$ ,  $-N(C_1-C_6 \text{ alkyl})_2$ ,  $-N-SO_2-C_1-C_6 \text{ alkyl}$ , or  $-SO_2-C_1-C_6 \text{ alkyl}$ ;

20  $R_3$  is selected from H,  $-CF_3$ ,  $C_1-C_6 \text{ lower alkyl}$ ,  $C_1-C_6 \text{ lower alkoxy}$ ,  $C_3-C_{10} \text{ cycloalkyl}$ ,  $-C_1-C_6 \text{ alkyl}$ ,  $-C_3-C_{10} \text{ cycloalkyl}$ ,  $-CHO$ , halogen,  $-(CH_2)_n C(O)NH_2$  or a moiety of the formula  $-L^1-M^1$ ;

25  $L^1$  indicates a linking or bridging group of the formulae  $-(CH_2)_n-$ ,  $-S-$ ,  $-O-$ ,  $-C(O)-$ ,  $-(CH_2)_n-C(O)-$ ,  $-(CH_2)_n-C(O)-(CH_2)_n-$ ,  $-(CH_2)_n-O-(CH_2)_n-$ , or  $-(CH_2)_n-S-(CH_2)_n-$ ,  $C(O)C(O)X$ , or  $-(CH_2)_n-N-(CH_2)_n$ ;  
where X is O or N

$M^1$  is selected from:

30 a) H, the group of  $C_1-C_6 \text{ lower alkyl}$ ,  $C_1-C_6 \text{ lower alkoxy}$ ,  $C_3-C_{10} \text{ cycloalkyl}$ , phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted

Sub  
Al  
cont

00677021.092900

- 162 -

5 by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, or -CF<sub>3</sub>; or

b) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, isothiazole, isoxazole, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazole, pyrazoline, imidazole, tetrazole, oxathiazole, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, or -CF<sub>3</sub>; or

15

c) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O including, but not limited to, pyran, pyridine, pyrazine, pyrimidine, pyridazine, piperidine, piperazine, tetrazine, thiazine, thiadizine, oxazine, or morpholine, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -CHO, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, -CF<sub>3</sub> or -OH; or

20

d) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including, but not limited to benzofuran, chromene, indole, isoindole, indoline, isoindoline, naphthalene, purine, indolizine, indazole, quinoline, isoquinoline, quinolizine, quinazoline, cinnoline, phthalazine, or naphthyridine, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -CHO, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, -CF<sub>3</sub> or -OH;

25

30

006260-T2072960

Sub  
#1  
10  
am


- 163 -

5

*Sub*  
*AF*

$R_4$  is selected from the group of  $C_1$ - $C_6$  lower alkyl,  $C_1$ - $C_6$  lower alkoxy,  $-(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl,  $-(CH_2)_n$ -S- $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl,  $-(CH_2)_n$ -O- $(CH_2)_n$ - $C_3$ - $C_6$  cycloalkyl, or the groups of:

10 a) a moiety of the formulae  $-(CH_2)_n$ -A,  $-(CH_2)_n$ -S-A, or  $-(CH_2)_n$ -O-A, wherein A is the moiety:




wherein

D is H,  $C_1$ - $C_6$  lower alkyl,  $C_1$ - $C_6$  lower alkoxy, or  $-CF_3$ ;

15 B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen,  $-CF_3$ ,  $-OH$ ,  $-C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy, or  $-NO_2$ ;

20  $R_5$  is selected from  $-COOH$ ,  $-C(O)-COOH$ ,  $-(CH_2)_n$ - $C(O)-COOH$ ,  $-(CH_2)_n$ - $COOH$ ,  $(CH_2)_n$ - $CH=CH-COOH$ ,  $-(CH_2)_n$ -tetrazole, or



or a moiety selected from the formulae  $-L^3-M^3$ ;


25

006260-1207960

- 164 -

5 wherein  $L^3$  is a bridging or linking moiety selected from a chemical bond,  $-(CH_2)_n-$ ,  $-SO_2-$ ,  $-C(O)-$ ,  $-(CH_2)_n-C(O)-$ ,  $-(CH_2)_n-C(O)-(CH_2)_n-$ ,  $-(CH_2)_n-O-(CH_2)_n-$ ,  $-(CH_2)_n-S-(CH_2)_n-$ ,  $-(CH_2)_n-SO-(CH_2)_n-$ ,  $-(CH_2)_n-SO_2-(CH_2)_n-$ , or  $-(CH_2)_n-CH=CH-(CH_2)_n-O-$ ;

$M^3$  is selected from the group of  $-COOH$ ,  $-(CH_2)_n-COOH$ ,  $-(CH_2)_n-C(O)-COOH$ , tetrazole,




where  $R_8$ ,  $R_9$  can be attached anywhere in the cyclic or bicyclic system,  
 $n$  is an integer from 0 to 3;

$R_8$ , in each appearance, is independently selected from H,  $-COOH$ ,  $-(CH_2)_n-COOH$ ,  $-(CH_2)_n-C(O)-COOH$ , tetrazole,  $-C(O)-NH_2$ ,  $-(CH_2)_n-C(O)-NH_2$ ,

Sub  
 H1  
 cont

006260" T2027960

- 165 -




*Substituent*  
 5  $n$  is an integer from 0 to 3;

$R_9$  is selected from H, halogen,  $-\text{CF}_3$ ,  $-\text{OH}$ ,  $-\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{COOH}$ ,  
 10  $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$ ,  $-\text{C}_1-\text{C}_6$  alkyl,  $-\text{O}-\text{C}_1-\text{C}_6$  alkyl,  $-\text{NH}(\text{C}_1-\text{C}_6$  alkyl), or  $-\text{N}(\text{C}_1-\text{C}_6$  alkyl)<sub>2</sub>;

$n$  is an integer from 0 to 3;

with a proviso that the complete moiety at the indole or indoline 1-  
 position created by any combination of  $R_5$ ,  $R_8$ ,  $R_9$ , shall contain at least one acidic  
 15 moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the  
 formulae:  $-\text{C}(\text{O})-\text{NH}_2$ ,  $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{NH}_2$ ,




$n$  is an integer from 0 to 3;

20 or a pharmaceutically acceptable salt thereof.

6. A compound of Claim 1 having the formulae:

0967021-092900

- 166 -




wherein:

R<sub>1</sub> is selected from H, halogen, -CF<sub>3</sub>, -OH, -C<sub>1</sub>-C<sub>10</sub> alkyl, preferably -C<sub>1</sub>-C<sub>6</sub> alkyl, -S-C<sub>1</sub>-C<sub>10</sub> alkyl, preferably -S-C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -HN(C<sub>1</sub>-C<sub>6</sub>), -N(C<sub>1</sub>-C<sub>6</sub>)<sub>2</sub>, phenyl, -O-phenyl, -S-phenyl, benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, -CF<sub>3</sub>, or -OH;

or R<sub>1</sub> and R<sub>1</sub>' are independently a moiety of the formulae:

or a moiety of the formulae:



006677021-092900

Sub  
A1  
cm

- 167 -

5

*Sub*  
*1*  
*mt*

$R_6$  is selected from H,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $-C(O)CH_3$  phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $-NO_2$ ,  $-NH_2$ ,  $-CN$ ,  $-CF_3$ , or  $-OH$ ;

10

$R_7$  is selected from  $-(CH_2)_n-COOH$ ,  $-(CH_2)_n-N-(C_1-C_6 \text{ alkyl})_2$ ,  $-(CH_2)_n-NH-(C_1-C_6 \text{ alkyl})$ ,  $-CF_3$ ,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_5$  cycloalkyl,  $C_1$ - $C_6$  alkoxy,  $-NH-(C_1-C_6 \text{ alkyl})$ ,  $-N-(C_1-C_6 \text{ alkyl})_2$ , pyridinyl, thienyl, furyl, pyrrolyl, quinolyl,  $(CH_2)_n$ phenyl, phenyl, -O-phenyl, benzyl, -O-benzyl, adamantyl, or morpholinyl,  $-(CH_2)_n$ -phenyl-O-phenyl, -  
15  $(CH_2)_n$ -phenyl- $CH_2$ -phenyl,  $-(CH_2)_n$ -O-phenyl- $CH_2$ -phenyl,  $-(CH_2)_n$ -phenyl-(O- $CH_2$ -phenyl)<sub>2</sub>, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $-NH_2$ ,  $-NO_2$ ,  $-CF_3$ ,  $CO_2H$ , or  $-OH$ ;

20

$R_2$  is selected from H, halogen,  $-CF_3$ ,  $-OH$ ,  $-C_1$ - $C_{10}$  alkyl, preferably  $-C_1$ - $C_6$  alkyl,  $C_1$ - $C_{10}$  alkoxy, preferably  $C_1$ - $C_6$  alkoxy,  $-CHO$ ,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-NH-C_1-C_6$  alkyl,  $-N(C_1-C_6 \text{ alkyl})_2$ ,  $-N-SO_2-C_1-C_6$  alkyl, or  $-SO_2-C_1-C_6$  alkyl;

25

$R_3$  is selected from H,  $-CF_3$ ,  $C_1$ - $C_6$  lower alkyl,  $C_1$ - $C_6$  lower alkoxy,  $C_3$ - $C_{10}$  cycloalkyl,  $-C_1$ - $C_6$  alkyl,  $-C_3$ - $C_{10}$  cycloalkyl,  $-CHO$ , halogen,  $(CH_2)_n C(O)NH_2$  or a moiety of the formula  $-L^1-M^1$ :

30

$L^1$  indicates a linking or bridging group of the formulae  $-(CH_2)_n$ -,  $-C(O)-$ ,  $-(CH_2)_n-C(O)-$ ,  $-(CH_2)_n-C(O)-(CH_2)_n$ -,  $-(CH_2)_n-O-(CH_2)_n$ -, or  $-(CH_2)_n-S-(CH_2)_n$ -,  $C(O)C(O)X$ ,  $-(CH_2)_n-N-(CH_2)_n$ ;

006260-1204960



- 168 -


5  $M^1$  is selected from:

10 a) H, the group of  $C_1-C_6$  lower alkyl,  $C_1-C_6$  lower alkoxy,  $C_3-C_{10}$  cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen,  $C_1-C_{10}$  alkyl, preferably  $C_1-C_6$  alkyl,  $C_1-C_{10}$  alkoxy, preferably  $C_1-C_6$  alkoxy,  $-NO_2$ ,  $-NH_2$ ,  $-CN$ , or  $-CF_3$ ; or

$R_4$  is selected from the group of  $C_1-C_6$  lower alkyl,  $C_1-C_6$  lower alkoxy,  $-(CH_2)_n-C_3-C_6$  cycloalkyl,  $-(CH_2)_n-S-(CH_2)_n-C_3-C_5$  cycloalkyl,  $-(CH_2)_n-O-(CH_2)_n-C_3-C_5$  cycloalkyl, or the groups of:

15

a) a moiety of the formulae  $-(CH_2)_n-A$ ,  $-(CH_2)_n-S-A$ , or  $-(CH_2)_n-O-A$ , wherein A is the moiety:



wherein

20 D is H,  $C_1-C_6$  lower alkyl,  $C_1-C_6$  lower alkoxy, or  $-CF_3$ ;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen,  $-CF_3$ ,  $-OH$ ,  $-C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy, or  $-NO_2$ ;

25

$R_5$  is selected from  $-COOH$ ,  $-C(O)-COOH$ ,  $-(CH_2)_n-C(O)-COOH$ ,  $-(CH_2)_n-COOH$ ,  $(CH_2)_n-CH=CH-COOH$ ,  $-(CH_2)_n$ -tetrazole, or a moiety selected from the formulae  $-L^3-M^3$ ;


Sub  
A1  
Int

006660-1206960

- 169 -

- 5 wherein  $L^3$  is a bridging or linking moiety selected from a chemical bond,  $-(CH_2)_n-$ ,  $-(CH_2)_n-C(O)-(CH_2)_n-$ ,  $-(CH_2)_n-O-(CH_2)_n-$ ,  $-(CH_2)_n-S-(CH_2)_n-$ ,  $-(CH_2)_n-SO-(CH_2)_n-$ ,  $-(CH_2)_n-SO_2-(CH_2)_n-$ , or  $-(CH_2)_n-CH=CH-(CH_2)_n-O-$ ;

$M^3$  is selected from the group of  $-COOH$ ,  $-(CH_2)_n-COOH$ ,  $-(CH_2)_n-C(O)-COOH$ , tetrazole,




where  $R_8$ ,  $R_9$  can be attached anywhere in the cyclic or bicyclic system,  
 $n$  is an integer from 0 to 3;

$R_8$ , in each appearance, is independently selected from H,  $-COOH$ ,  $-(CH_2)_n-COOH$ ,  $-(CH_2)_n-C(O)-COOH$ , tetrazole,  $-C(O)-NH_2$ ,  $-(CH_2)_n-C(O)-NH_2$ ,

Sub  
 A1  
 cont

006260-120/2950

- 170 -



5

*n* is an integer from 0 to 3;


*R*<sub>9</sub> is selected from H, halogen, -CF<sub>3</sub>, -OH, -COOH, -(CH<sub>2</sub>)<sub>n</sub>-COOH, -(CH<sub>2</sub>)<sub>n</sub>-C(O)-COOH, -C<sub>1</sub>-C<sub>6</sub> alkyl, -O-C<sub>1</sub>-C<sub>6</sub> alkyl, -NH(C<sub>1</sub>-C<sub>6</sub> alkyl), or -N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>;

10

*n* is an integer from 0 to 3;

with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of *R*<sub>5</sub>, *R*<sub>8</sub>, *R*<sub>9</sub>, shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: -C(O)-NH<sub>2</sub>, -(CH<sub>2</sub>)<sub>n</sub>-C(O)-NH<sub>2</sub>,

15



*n* is an integer from 0 to 3;

or a pharmaceutically acceptable salt thereof.


20

09677021-092900

Sub  
#1  
Qm

- 171 -


5 7. A compound of Claim 1 having the formulae:




wherein:

$R_1$  and  $R_{1'}$  are independently selected from H, halogen,  $-CF_3$ ,  $-OH$ ,  $-C_1-C_{10}$  alkyl, preferably  $-C_1-C_6$  alkyl,  $-S-C_1-C_{10}$  alkyl, preferably  $-S-C_1-C_6$  alkyl,  $C_1-C_{10}$  alkoxy, preferably  $C_1-C_6$  alkoxy,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-HN(C_1-C_6)$ ,  $-N(C_1-C_6)_2$ , phenyl,  $-O$ -phenyl,  $-S$ -phenyl, benzyl,  $-O$ -benzyl,  $-S$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy,  $-NO_2$ ,  $-NH_2$ ,  $-CN$ ,  $-CF_3$ , or  $-OH$ ;

or  $R_1$  and  $R_{1'}$  are independently a moiety of the formulae:



- 172 -



*Sub  
A  
Am*  
10  $\text{R}_6$  is selected from H,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkoxy, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{NO}_2$ ,  $-\text{NH}_2$ ,  $-\text{CN}$ ,  $-\text{CF}_3$ , or  $-\text{OH}$ ;

15  $\text{R}_7$  is selected from  $-\text{OH}$ ,  $-\text{CF}_3$ ,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$ ,  $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$ , pyridinyl, thienyl, furyl, pyrrolyl, phenyl, -O-phenyl, benzyl, -O-benzyl, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen,  $-\text{CN}$ ,  $\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{NO}_2$ ,  $-\text{NH}_2$ ,  $-\text{CF}_3$ , or  $-\text{OH}$ ;

20  $\text{R}_2$  is selected from H, halogen,  $-\text{CF}_3$ ,  $-\text{OH}$ ,  $-\text{C}_1\text{-C}_{10}$  alkyl, preferably  $-\text{C}_1\text{-C}_6$  alkyl,  $\text{C}_1\text{-C}_{10}$  alkoxy, preferably  $\text{C}_1\text{-C}_6$  alkoxy,  $-\text{CHO}$ ,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $-\text{NH}_2$ ,  $-\text{NH-C}_1\text{-C}_6$  alkyl,  $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$ ,  $-\text{N-SO}_2\text{-C}_1\text{-C}_6$  alkyl, or  $-\text{SO}_2\text{-C}_1\text{-C}_6$  alkyl;

25  $\text{R}_3$  is selected from H,  $-\text{C}_1\text{-C}_{10}$  alkyl, preferably  $-\text{C}_1\text{-C}_6$  alkyl,  $-(\text{CH}_2)\text{-OH}$ ,  $(\text{CH}_2)_n\text{C}(\text{O})\text{NH}_2$ ,  $-\text{CH}_2\text{-O}(\text{C}_1\text{-C}_6 \text{ alkyl})$ ,  $-\text{CH}_2\text{-O-CH}_2\text{-phenyl}$ ,  $-\text{CH}_2\text{-N}(\text{C}_1\text{-C}_6 \text{ alkyl})$ ,  $-\text{CH}_2\text{-N-CH}_2\text{-phenyl}$ , the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen,  $-\text{CF}_3$  or  $-\text{C}_1\text{-C}_6$  alkyl;

X is O or N

n = 0 or 1;


006260-1204960

- 173 -

*Sub  
not A1*

5

$R_4$  is a moiety of the formulae  $-(CH_2)_n-A$ ,  $-(CH_2)_n-S-A$ , or  $-(CH_2)_n-O-A$ , wherein A is the moiety:




wherein


10 D is H,  $C_1-C_6$  lower alkyl,  $C_1-C_6$  lower alkoxy, or  $-CF_3$ ;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen,  $-CF_3$ ,  $-OH$ ,  $-C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy, or  $-NO_2$ ;

15  $R_5$  is a moiety selected from the groups of:



or



006260-T20-1960

20

- 174 -

5 wherein  $L^1$  is a bridging or linking moiety selected from a chemical bond,  $-(CH_2)_n-$ ,  $-(CH_2)_n-C(O)-(CH_2)_n-$ ,  $-(CH_2)_n-O-(CH_2)_n-$ ,  $-(CH_2)_n-S-(CH_2)_n-$ ,  $-(CH_2)_n-SO-(CH_2)_n-$ ,  $-(CH_2)_n-SO_2-(CH_2)_n-$ , or  $-(CH_2)_n-CH=CH-(CH_2)_n-O-$ ;


where  $n'$  is an integer from 0 to 5;

10  $R_9$  is selected from  $-CF_3$ ,  $-C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy,  $-NH(C_1-C_6$  alkyl), or  $-N(C_1-C_6$  alkyl) $_2$ ,

$n$  in each instance is independently selected as an integer from 0 to 3;

or a pharmaceutically acceptable salt thereof.

8. A compound of Claim 1 having the formulae:



15 wherein:

$R_1$  is selected from H, halogen,  $-CF_3$ ,  $-OH$ ,  $-C_1-C_{10}$  alkyl, preferably  $-C_1-C_6$  alkyl,  $-S-C_1-C_{10}$  alkyl, preferably  $-S-C_1-C_6$  alkyl,  $C_1-C_{10}$  alkoxy, preferably  $C_1-C_6$  alkoxy,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-HN(C_1-C_6)$ ,  $-N(C_1-C_6)_2$ , phenyl,  $-O$ -phenyl,  $-S$ -phenyl,

- 175 -


5 benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, -NO<sub>2</sub>, -NH<sub>2</sub>, -CN, -CF<sub>3</sub>, or -OH;

*Substituted*  
10 R<sub>2</sub> is selected from H, halogen, -CF<sub>3</sub>, -OH, -C<sub>1</sub>-C<sub>10</sub> alkyl, preferably -C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, preferably C<sub>1</sub>-C<sub>6</sub> alkoxy, -CHO, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -NH-C<sub>1</sub>-C<sub>6</sub> alkyl, -N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>, -N-SO<sub>2</sub>-C<sub>1</sub>-C<sub>6</sub> alkyl, or -SO<sub>2</sub>-C<sub>1</sub>-C<sub>6</sub> alkyl;

15 R<sub>3</sub> is selected from H, -C<sub>1</sub>-C<sub>10</sub> alkyl, preferably -C<sub>1</sub>-C<sub>6</sub> alkyl, -(CH<sub>2</sub>)-OH, (CH<sub>2</sub>)<sub>n</sub>C(O)NH<sub>2</sub>, -CH<sub>2</sub>-O-(C<sub>1</sub>-C<sub>6</sub> alkyl), -CH<sub>2</sub>-O-CH<sub>2</sub>-phenyl, -CH<sub>2</sub>-N-(C<sub>1</sub>-C<sub>6</sub> alkyl), -CH<sub>2</sub>-N-CH<sub>2</sub>-phenyl, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, -CF<sub>3</sub> or -C<sub>1</sub>-C<sub>6</sub> alkyl;

n = 0 or 1.

20 R<sub>4</sub> is a moiety of the formulae -(CH<sub>2</sub>)<sub>n</sub>-A, -(CH<sub>2</sub>)<sub>n</sub>-S-A, or -(CH<sub>2</sub>)<sub>n</sub>-O-A, wherein A is the moiety:



wherein

D is H, C<sub>1</sub>-C<sub>6</sub> lower alkyl, C<sub>1</sub>-C<sub>6</sub> lower alkoxy, or -CF<sub>3</sub>;

25 B and C are independently selected from phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen, -CF<sub>3</sub>, -OH, -C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, or -NO<sub>2</sub>;


006260-1202960



- 176 -

5

R<sub>5</sub> is a moiety selected from the groups of:



10

wherein L<sup>1</sup> is a bridging or linking moiety selected from a chemical bond, -(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>n</sub>-C(O)-(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>n</sub>-S-(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>n</sub>-SO-(CH<sub>2</sub>)<sub>n</sub>-, -(CH<sub>2</sub>)<sub>n</sub>-SO<sub>2</sub>-(CH<sub>2</sub>)<sub>n</sub>-, or -(CH<sub>2</sub>)<sub>n</sub>-CH=CH-(CH<sub>2</sub>)<sub>n</sub>-O-;

where n = 0-5

15

R<sub>9</sub> is selected from -CF<sub>3</sub>, -C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, -NH(C<sub>1</sub>-C<sub>6</sub> alkyl), or -N(C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>,

n in each instance is independently selected as an integer from 0 to 3


20

or a pharmaceutically acceptable salt thereof

0067021-092900

- 177 -

5            9.    A compound of Claim 1 having the formulae:



wherein:

$R_1$  is selected from H, halogen,  $-\text{CF}_3$ ,  $-\text{OH}$ ,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $-\text{NH}_2$ ,  $-\text{HN}(\text{C}_1\text{-C}_6)$ ,  $-\text{N}(\text{C}_1\text{-C}_6)_2$ , phenyl,  $-\text{N-SO}_2\text{-C}_1\text{-C}_6$  alkyl, or  $-\text{SO}_2\text{-C}_1\text{-C}_6$  alkyl;


$R_2$  is selected from H, halogen,  $-\text{CF}_3$ ,  $-\text{OH}$ ,  $-\text{CN}$ ,  $-\text{NO}_2$ ,  $-\text{NH}_2$ ,  $-\text{NH-C}_1\text{-C}_6$  alkyl,  $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$ ,  $-\text{N-SO}_2\text{-C}_1\text{-C}_6$  alkyl, or  $-\text{SO}_2\text{-C}_1\text{-C}_6$  alkyl;

$R_3$  is selected from H,  $-\text{C}_1\text{-C}_{10}$  alkyl, preferably  $-\text{C}_1\text{-C}_6$  alkyl,  $-(\text{CH}_2)\text{-OH}$ ,  $(\text{CH}_2)_n\text{C(O)NH}_2$ ,  $-\text{CH}_2\text{-O-(C}_1\text{-C}_6 \text{ alkyl)}$ ,  $-\text{CH}_2\text{-O-CH}_2\text{-phenyl}$ ,  $-\text{CH}_2\text{-N-(C}_1\text{-C}_6 \text{ alkyl)}$ ,  $-\text{CH}_2\text{-N-CH}_2\text{-phenyl}$ , the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen,  $-\text{CF}_3$  or  $-\text{C}_1\text{-C}_6$  alkyl;


$n = 0$  or  $1$ .

$R_5$  is a moiety selected from the groups of:

- 178 -



or



wherein  $L^1$  is a bridging or linking moiety selected from a chemical bond,  $-(CH_2)_{n'}$ -,  $-(CH_2)_{n'}-C(O)-(CH_2)_{n'}$ -,  $-(CH_2)_{n'}-O-(CH_2)_{n'}$ -,  $-(CH_2)_{n'}-S-(CH_2)_{n'}$ -,  $-(CH_2)_{n'}-SO-(CH_2)_{n'}$ -,  $-(CH_2)_{n'}-SO_2-(CH_2)_{n'}$ -, or  $-(CH_2)_{n'}-CH=CH-(CH_2)_{n'}-O$ -;

10  $n'$  in each instance is independently selected as an integer from 0 to 5;  
or a pharmaceutically acceptable salt thereof.

15 10. A compound of Claim 1 which is 4-{[(E)-4-(3-benzhydryl-5-chloro-2-methyl-1H-indol-1-yl)-2-butenyl]oxy}benzoic acid or a pharmaceutically acceptable salt thereof.

20 11. A compound of Claim 1 which is 4-[2-(3-benzhydryl-5-chloro-2-methyl-1H-indol-1-yl)ethoxy]benzoic acid or a pharmaceutically acceptable salt thereof.

006260-12207960

- 179 -

5           12.    A compound of Claim 1 which is 3-{4-[2-(3-benzhydryl-5-chloro-2-methyl-1H-indol-1-yl)ethoxy]phenyl}propanoic acid or a pharmaceutically acceptable salt thereof.

10           13.    A compound of Claim 1 which is 3-(4-{[2-(3-benzhydryl-6-chloro-1H-indol-1-yl)ethyl]sulfonyl}phenyl)propanoic acid or a pharmaceutically acceptable salt thereof.

15           14.    A compound of Claim 1 which is 4-{[2-(3-benzhydryl-6-chloro-1H-indol-1-yl)ethyl]sulfonyl}benzoic acid or a pharmaceutically acceptable salt thereof.

            15.    A compound of Claim 1 which is 4-[2-(3-benzhydryl-2-methyl-1H-indol-1-yl)ethoxy]benzoic acid or a pharmaceutically acceptable salt thereof.

20           16.    A method of inhibiting the phospholipase activity of an enzyme in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

25           17.    A method of treating or preventing an inflammatory response in a mammal in need thereof, the method comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

30           18.    The method of Claim 17 wherein the inflammatory response is associated with inflammatory bowel disease.

0067021-092900

- 180 -

5           19.    The method of Claim 17 wherein the inflammatory response is  
associated with osteoarthritis, psoriatic arthritis or rheumatoid arthritis.

          20.    A pharmaceutical composition comprising a therapeutically effective  
amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and  
10   a pharmaceutically acceptable carrier.

006260-1202960